Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Forbes29d
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
you may be eligible to pay as low as $25 for a one- or three-month supply of Zepbound,” Eli Lilly says. “One month is defined as 28 days and 4 pens. Three months is defined as 84 days and up ...
pharmaphorum8d
Lilly preps for rollout of its connected diabetes system
After years of preparation, Eli Lilly is on the brink of launching a ... The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device ...
Reuters28d
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...
pharmaphorum5d
Lilly doubles down on Dexcom tech for connected insulin devices
Two years ago, Eli Lilly started working with Dexcom to integrate ... app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the basis of the ...
Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...